Base de dados : MEDLINE
Pesquisa : D02.455.326.271.665.400 [Categoria DeCS]
Referências encontradas : 91 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 10 ir para página                        

  1 / 91 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:22870266
[Au] Autor:Cohen JM; Fagin AP; Hariton E; Niska JR; Pierce MW; Kuriyama A; Whelan JS; Jackson JL; Dimitrakoff JD
[Ad] Endereço:Harvard Medical School, Boston, Massachusetts, United States of America.
[Ti] Título:Therapeutic intervention for chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): a systematic review and meta-analysis.
[So] Source:PLoS One;7(8):e41941, 2012.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) has been treated with several different interventions with limited success. This meta-analysis aims to review all trials reporting on therapeutic intervention for CP/CPPS using the National Institutes of Health-Chronic Prostatitis Symptom Index (NIH-CPSI). METHODS: We searched Medline, PubMed, the Cochrane Pain, Palliative & Supportive Care Trials, the Cochrane Register of Controlled Trials, CINAHL, ClinicalTrials.gov, and the NIDDK website between 1947 and December 31, 2011 without language or study type restrictions. All RCTs for CP/CPPS lasting at least 6 weeks, with a minimum of 10 participants per arm, and using the NIH-CPSI score, the criterion standard for CP/CPPS, as an outcome measure were included. Data was extracted from each study by two independent reviewers. Gillbraith and I-squared plots were used for heterogeneity testing and Eggers and Peters methods for publication bias. Quality was assessed using a component approach and meta-regression was used to analyze sources of heterogeneity. RESULTS: Mepartricin, percutaneous tibial nerve stimulation (PTNS), and triple therapy comprised of doxazosin + ibuprofen + thiocolchicoside (DIT) resulted in clinically and statistically significant reduction in NIH-CPSI total score. The same agents and aerobic exercise resulted in clinically and statistically significant NIH-CPSI pain domain score reduction. Acupuncture, DIT, and PTNS were found to produce statistically and clinically significant reductions in the NIH-CPSI voiding domain. A statistically significant placebo effect was found for all outcomes and time analysis showed that efficacy of all treatments increased over time. Alpha-blockers, antibiotics, and combinations of the two failed to show statistically or clinically significant NIH-CPSI reductions. CONCLUSION: Results from this meta-analysis reflect our current inability to effectively manage CP/CPPS. Clinicians and researchers must consider placebo effect and treatment efficacy over time and design studies creatively so we can more fully elucidate the etiology and role of therapeutic intervention in CP/CPPS.
[Mh] Termos MeSH primário: Dor Crônica/terapia
Dor Pélvica/terapia
Prostatite/terapia
[Mh] Termos MeSH secundário: Antibacterianos/uso terapêutico
Doença Crônica
Colchicina/análogos & derivados
Colchicina/uso terapêutico
Seres Humanos
MEDLINE
Masculino
Mepartricina/uso terapêutico
Ensaios Clínicos Controlados Aleatórios como Assunto
Estimulação Elétrica Nervosa Transcutânea/métodos
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; REVIEW
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 11121-32-7 (Mepartricin); SML2Y3J35T (Colchicine); T1X8S697GT (thiocolchicoside)
[Em] Mês de entrada:1302
[Cu] Atualização por classe:170220
[Lr] Data última revisão:
170220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:120808
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0041941


  2 / 91 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
[PMID]:21736764
[Au] Autor:Le B; Schaeffer AJ
[Ad] Endereço:Department of Urology, Northwestern University Medical Centre, Chicago, USA.
[Ti] Título:Chronic prostatitis.
[So] Source:BMJ Clin Evid;2011, 2011 Jul 04.
[Is] ISSN:1752-8526
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Chronic prostatitis can cause pain and urinary symptoms, and usually occurs without positive bacterial cultures from prostatic secretions (known as chronic abacterial prostatitis or chronic pelvic pain syndrome [CP/CPPS]). Bacterial infection can result from urinary tract instrumentation, but the cause and natural history of CP/CPPS are unknown. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of treatments for chronic bacterial prostatitis? What are the effects of treatments for chronic abacterial prostatitis/chronic pelvic pain syndrome? We searched: Medline, Embase, The Cochrane Library, and other important databases up to August 2010 (Clinical Evidence reviews are updated periodically; please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA). RESULTS: We found 33 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions. CONCLUSIONS: In this systematic review, we present information relating to the effectiveness and safety of the following interventions: 5 alpha-reductase inhibitors, allopurinol, alpha-blockers, biofeedback, local injections of antimicrobial drugs, mepartricin, non-steroidal anti-inflammatory drugs (NSAIDs), oral antimicrobial drugs, pentosan polysulfate, prostatic massage, quercetin, radical prostatectomy, sitz baths, transurethral microwave thermotherapy, and transurethral resection.
[Mh] Termos MeSH primário: Mepartricina
Prostatite
[Mh] Termos MeSH secundário: Inibidores de 5-alfa Redutase/uso terapêutico
Doença Crônica
Seres Humanos
Masculino
Mepartricina/uso terapêutico
Poliéster Sulfúrico de Pentosana/uso terapêutico
Prostatite/tratamento farmacológico
Quercetina/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (5-alpha Reductase Inhibitors); 11121-32-7 (Mepartricin); 37300-21-3 (Pentosan Sulfuric Polyester); 9IKM0I5T1E (Quercetin)
[Em] Mês de entrada:1604
[Cu] Atualização por classe:110708
[Lr] Data última revisão:
110708
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:110709
[St] Status:MEDLINE


  3 / 91 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:16846466
[Au] Autor:Barbero R; Badino P; Odore R; Galmozzi MR; Cuniberti B; Zanatta R; Re G
[Ad] Endereço:Department of Animal Pathology, Division of Pharmacology & Toxicology, University of Torino, Grugliasco, Turin, Italy.
[Ti] Título:Mepartricin long-term administration regulates steroid hormone and adrenergic receptor concentrations in the prostate of aged rats.
[So] Source:J Vet Pharmacol Ther;29(4):289-97, 2006 Aug.
[Is] ISSN:0140-7783
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Mepartricin is a semi-synthetic macrolide antibiotic developed as a drug for the treatment of benign prostatic hyperplasia (BPH) in human patients. In the present study, aged rats are used as an experimental model to evaluate the effects of mepartricin on circulating hormone concentrations and prostate receptor concentrations, to compare these possible effects with clinical findings observed in long-term treated dogs. Fifty-six aged male rats were randomly divided into four experimental groups treated orally with 0 (group 1), 2 mg (group 2), 5 mg (group 3) and 20 mg (group 4) mepartricin/kg of body weight. for 28 days respectively. Serum oestradiol and testosterone concentrations were measured by radio-immune-assays methods. Binding assays were used to measure the prostate concentrations of oestrogen receptors (ER), androgen receptors (AnR), alpha(1)-adrenergic receptor (alpha(1)-AR), and beta-adrenerergic receptor (beta-AR) subtypes. Mepartricin induced a significant reduction of prostate weight and serum oestradiol concentrations. Serum testosterone concentrations were unaffected. The treatment induced a significant down-regulation of ER concentrations (P < 0.05) and a significant up-regulation of AnR (P < 0.05) in rat prostate. Mepartricin induced a significant (P < 0.05) dose-dependent up-regulation of alpha(1)-AR and beta(2)-AR. In contrast, the concentration of beta(3)-ARs was significantly decreased (P < 0.05) in treated animals. The increase in prostate beta(2)-AR concentrations observed in subjects treated with mepartricin may be a favourable element in the evolution of BPH, because of the role exerted by these receptors in the control of prostatic smooth muscle relaxation. Curiously, beta(3)-AR concentrations were significantly reduced in treated animals. Data collected suggest that the prostatic beta-AR expression might be strongly influenced by oestrogen deprivation (mepartricin treatment); therefore, the combination of oestrogen suppression (mepartricin) and adrenergic suppression (alpha(1)-AR blockers) may be proposed as a possible nonhormonal therapeutic strategy for the treatment of benign prostatic hyperplasia in dogs.
[Mh] Termos MeSH primário: Mepartricina/farmacologia
Receptores Adrenérgicos/efeitos dos fármacos
[Mh] Termos MeSH secundário: Administração Oral
Envelhecimento
Animais
Modelos Animais de Doenças
Doenças do Cão/tratamento farmacológico
Cães
Relação Dose-Resposta a Droga
Esquema de Medicação
Estradiol/sangue
Masculino
Mepartricina/administração & dosagem
Mepartricina/sangue
Hiperplasia Prostática/tratamento farmacológico
Hiperplasia Prostática/veterinária
Ratos
Testosterona/sangue
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Receptors, Adrenergic); 11121-32-7 (Mepartricin); 3XMK78S47O (Testosterone); 4TI98Z838E (Estradiol)
[Em] Mês de entrada:0608
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:060719
[St] Status:MEDLINE


  4 / 91 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
[PMID]:16698346
[Au] Autor:Dimitrakov JD; Kaplan SA; Kroenke K; Jackson JL; Freeman MR
[Ad] Endereço:Harvard Urological Diseases Research Center, Children's Hospital Boston, Harvard Medical School, Boston, Massachusetts 02115, USA. Jordan.Dimitrakov@childrens.harvard.edu
[Ti] Título:Management of chronic prostatitis/chronic pelvic pain syndrome: an evidence-based approach.
[So] Source:Urology;67(5):881-8, 2006 May.
[Is] ISSN:1527-9995
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Dor Pélvica/tratamento farmacológico
Prostatite/tratamento farmacológico
[Mh] Termos MeSH secundário: Antagonistas Adrenérgicos alfa/uso terapêutico
Adulto
Antibacterianos/uso terapêutico
Anti-Inflamatórios não Esteroides/uso terapêutico
Doença Crônica
Antagonistas de Estrogênios/uso terapêutico
Seres Humanos
Lactonas/uso terapêutico
Masculino
Mepartricina/uso terapêutico
Meia-Idade
Dor Pélvica/diagnóstico
Poliéster Sulfúrico de Pentosana/uso terapêutico
Prostatite/diagnóstico
Sulfonas/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; REVIEW
[Nm] Nome de substância:
0 (Adrenergic alpha-Antagonists); 0 (Anti-Bacterial Agents); 0 (Anti-Inflammatory Agents, Non-Steroidal); 0 (Estrogen Antagonists); 0 (Lactones); 0 (Sulfones); 0QTW8Z7MCR (rofecoxib); 11121-32-7 (Mepartricin); 37300-21-3 (Pentosan Sulfuric Polyester)
[Em] Mês de entrada:0605
[Cu] Atualização por classe:161019
[Lr] Data última revisão:
161019
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:060516
[St] Status:MEDLINE


  5 / 91 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:16257836
[Au] Autor:Shakuto S; Tsuchiya E
[Ad] Endereço:Department of Molecular Biotechnology, Graduate School of Advanced Sciences of Matter, Hiroshima University, Higashi-Hiroshima, Japan. shuji.shakuto@sanofi-aventis.com
[Ti] Título:Effects of mepartricin, a polyene macrolide antibiotic, on estrogen-induced hyperplastic growth of the dorsolateral prostate and seminal vesicle in immature castrated rats.
[So] Source:Scand J Urol Nephrol;39(5):358-65, 2005.
[Is] ISSN:0036-5599
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To investigate the effects of mepartricin, a polyene macrolide antibiotic, on estrogen-induced hyperplastic prostate and seminal vesicle (SV) growth in castrated rats. MATERIAL AND METHODS: Immature rats aged 3 weeks were castrated and left untreated for 1 week. Then, 17beta-estradiol benzoate (E(2)-BA) was subcutaneously injected at a dose of 10 microg/day twice weekly, and mepartricin was orally administered at doses of 2.5, 5 and 10 mg/kg once daily for 3 weeks. The weights and hydroxyproline contents of the prostate and SV, the activity of growth factors (GFs) in the dorsolateral prostate (DLP) and the serum estrogen level were measured. Histological examination of the prostate and SV was also performed. RESULTS: Mepartricin dose-dependently suppressed the increase in the serum estrogen level, the weights and hydroxyproline contents of the DLP and SV and the elevation of GF activity in the DLP induced by E(2)-BA treatment. Histological examination also revealed that treatment with mepartricin reduced collagen accumulation and thickening of the smooth muscle layer in the DLP and SV, and proliferation of the glandular epithelium in the DLP. CONCLUSIONS: These results suggest that mepartricin suppresses hyperplastic growth of the DLP and SV induced by estrogen in immature castrated rats, the underlying mechanism being a reduction in the serum estrogen level, thereby suppressing stromal cell proliferation and activation.
[Mh] Termos MeSH primário: Antibacterianos/uso terapêutico
Mepartricina/farmacologia
Hiperplasia Prostática/tratamento farmacológico
Glândulas Seminais/patologia
[Mh] Termos MeSH secundário: Animais
Castração
Modelos Animais de Doenças
Estradiol/análogos & derivados
Estradiol/toxicidade
Masculino
Hiperplasia Prostática/induzido quimicamente
Hiperplasia Prostática/patologia
Ratos
Ratos Sprague-Dawley
Glândulas Seminais/efeitos dos fármacos
Resultado do Tratamento
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 11121-32-7 (Mepartricin); 1S4CJB5ZGN (estradiol 3-benzoate); 4TI98Z838E (Estradiol)
[Em] Mês de entrada:0602
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:051101
[St] Status:MEDLINE


  6 / 91 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:15449383
[Au] Autor:Quintela MM
[Ad] Endereço:Pesquisadora do Centro de Estudos de Antropologia, Social (ISCTE, Portugal) e professora da Escola Superior de Enfermagem, Calouste Gulbenkian de Lisboa. Edifício ISCTE Av. das Forças Armadas 1600-083 - Lisboa, Portugal. maria-quintela@clix.pt
[Ti] Título:[Thermal knowledge and therapies: a comparative view of Portugal (São Pedro do Sul hot springs) and Brazil (Caldas da Imperatriz hot springs)].
[Ti] Título:Saberes e práticas termais: uma perspectiva comparada em Portugal (Termas de S. Pedro do Sul) e no Brasil (Caldas da Imperatriz)..
[So] Source:Hist Cienc Saude Manguinhos;11 Suppl 1:239-60, 2004.
[Is] ISSN:0104-5970
[Cp] País de publicação:Brazil
[La] Idioma:por
[Ab] Resumo:Based on nineteenth - and twentieth-century texts, the article discusses how medicine legitimized the therapeutic practice of thermalism as so-called 'scientific' knowledge, with the creation of therapeutic establishments and hot-springs resort. My research began in Portugal in 1996, where I produced an ethnography of experiences at the São Pedro do Sul hot springs. My research at Brazil's Caldas da Imperatriz, initiated in August 2001, is still underway.
[Mh] Termos MeSH primário: Balneologia/história
Fontes Termais
Mepartricina/história
[Mh] Termos MeSH secundário: Brasil
História do Século XIX
História do Século XX
Portugal
[Pt] Tipo de publicação:ENGLISH ABSTRACT; HISTORICAL ARTICLE; JOURNAL ARTICLE
[Nm] Nome de substância:
11121-32-7 (Mepartricin)
[Em] Mês de entrada:0411
[Cu] Atualização por classe:061115
[Lr] Data última revisão:
061115
[Sb] Subgrupo de revista:Q
[Da] Data de entrada para processamento:040929
[St] Status:MEDLINE


  7 / 91 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:14751338
[Au] Autor:De Rose AF; Gallo F; Giglio M; Carmignani G
[Ad] Endereço:Luciano Giuliani Urology Department, University of Genoa, Genoa, Italy.
[Ti] Título:Role of mepartricin in category III chronic nonbacterial prostatitis/chronic pelvic pain syndrome: a randomized prospective placebo-controlled trial.
[So] Source:Urology;63(1):13-6, 2004 Jan.
[Is] ISSN:1527-9995
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: To verify the efficacy of mepartricin versus placebo with regard to symptom improvement in patients with chronic nonbacterial prostatitis/chronic pelvic pain syndrome (CPPS) and to verify a relation between hormonal levels and clinical improvement in these patients. METHODS: Twenty-six patients with CPPS were included in our study and randomized into two groups of 13 subjects each. Group 1 patients were treated with mepartricin (40 mg daily) and group 2 patients with placebo. All patients underwent treatment for 60 days. At the beginning and end of therapy, all patients underwent evaluation, including a standardized history, physical examination, luteinizing hormone, follicle-stimulating hormone, testosterone, and beta-estradiol measurements, and a National Institutes of Health-Chronic Prostatitis Symptom Index (NIH-CPSI) questionnaire. RESULTS: We observed a decrease in the total NIH-CPSI score from 25.0 to 10.0 in group 1 and from 25.0 to 20.0 in group 2, revealing a 60% and 20% improvement in groups 1 and 2, respectively. A statistically significant decrease was observed with regard to pain (from 11.0 to 4.0 and from 10.0 to 8.0, respectively) and quality of life (from 10.0 to 5.0 and 10.0 to 9.0, respectively). No statistically significant difference was observed in urinary dysfunctions. The luteinizing hormone, follicle-stimulating hormone, and testosterone values were similar in both groups before and after treatment; the 17-beta-estradiol levels were significantly lower in group 1 compared with group 2 at the end of the study. CONCLUSIONS: Mepartricin provides significant symptomatic improvement in men with CPPS compared with placebo. The role of mepartricin in decreasing estrogen plasmatic levels and their concentration in the prostate may account for this clinical improvement.
[Mh] Termos MeSH primário: Estradiol/sangue
Moduladores de Receptor Estrogênico/uso terapêutico
Mepartricina/uso terapêutico
Dor Pélvica/tratamento farmacológico
Prostatite/tratamento farmacológico
[Mh] Termos MeSH secundário: Adulto
Anti-Infecciosos/farmacologia
Anti-Infecciosos/uso terapêutico
Doença Crônica
Moduladores de Receptor Estrogênico/farmacologia
Hormônio Foliculoestimulante/sangue
Seres Humanos
Absorção Intestinal/efeitos dos fármacos
Hormônio Luteinizante/sangue
Masculino
Mepartricina/farmacologia
Meia-Idade
Estudos Prospectivos
Testosterona/sangue
Resultado do Tratamento
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Anti-Infective Agents); 0 (Estrogen Receptor Modulators); 11121-32-7 (Mepartricin); 3XMK78S47O (Testosterone); 4TI98Z838E (Estradiol); 9002-67-9 (Luteinizing Hormone); 9002-68-0 (Follicle Stimulating Hormone)
[Em] Mês de entrada:0406
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:040131
[St] Status:MEDLINE


  8 / 91 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:11799846
[Au] Autor:Barone D; Peroglio F; Toso E; Bruzzese T
[Ad] Endereço:LCG-RBM, Laboratories & Clinics Group, Ricerche Biomediche Antoine Marxer S.p.A., Colleretto Giacosa, Turin, Italy.
[Ti] Título:Binding of mepartricin to sex hormones, a key factor of its activity on benign prostatic hyperplasia.
[So] Source:Arzneimittelforschung;51(12):984-90, 2001.
[Is] ISSN:0004-4172
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:Androgens and estrogens, mainly testosterone (TES) and dihydrotestosterone (DHT) and 17 beta-estradiol (EST), are widely recognized to regulate the prostate growth and their imbalance with aging, leading to reduction of androgens and relative increase of estrogens, may be responsible for the development of benign prostatic hyperplasia (BPH). Mepartricin (CAS 11121-32-7), a polyene drug for medical treatment of BPH, was assayed in vitro for its ability to bind with 14C-labelled sex hormones, by incubation in buffered saline, serum and bile, followed by centrifugation and dosing of the radioactivity in the supernatant. It proved effective in complexing up to 90% of TES and DHT in buffered saline and up to 80% of EST in bile. Due to minimal absorption of oral mepartricin and to much higher enterohepatic circulation for estrogens than for androgens, the binding effect of mepartricin on EST in the gut should be of particular pharmacological relevance to explain its mechanism of action on BPH.
[Mh] Termos MeSH primário: Hormônios Esteroides Gonadais/metabolismo
Antagonistas de Hormônios/metabolismo
Antagonistas de Hormônios/uso terapêutico
Mepartricina/metabolismo
Mepartricina/uso terapêutico
Hiperplasia Prostática/tratamento farmacológico
Hiperplasia Prostática/metabolismo
[Mh] Termos MeSH secundário: Animais
Bile/metabolismo
Proteínas Sanguíneas/metabolismo
Bovinos
Centrifugação
Di-Hidrotestosterona/metabolismo
Estradiol/metabolismo
Vesícula Biliar/metabolismo
Seres Humanos
Técnicas In Vitro
Masculino
Ligação Proteica
Testosterona/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Blood Proteins); 0 (Gonadal Steroid Hormones); 0 (Hormone Antagonists); 08J2K08A3Y (Dihydrotestosterone); 11121-32-7 (Mepartricin); 3XMK78S47O (Testosterone); 4TI98Z838E (Estradiol)
[Em] Mês de entrada:0202
[Cu] Atualização por classe:141120
[Lr] Data última revisão:
141120
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:020122
[St] Status:MEDLINE


  9 / 91 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:11723437
[Au] Autor:Saita A; Morgia G; Branchina A; Giammusso B; Iurato C; Malacasa E; Motta M
[Ad] Endereço:Divisione Clinicizzata di Nefrologia Chirurgica-Urologia, Università degli Studi, Catania, Italy.
[Ti] Título:[Mepartricine and prostatitis. Clinical experience and rationale for use].
[Ti] Título:Mepartricina e prostatiti. Esperienza clinica e razionale d'impiego.
[So] Source:Minerva Urol Nefrol;53(3):129-33, 2001 Sep.
[Is] ISSN:0393-2249
[Cp] País de publicação:Italy
[La] Idioma:ita
[Ab] Resumo:BACKGROUND: The purpose of this study was to report our experience on the use of Mepartricine in the treatment of chronic and sub-acute prostatitis and to analyse, on the basis of the literature, the role of estrogens, the target of Mepartricine in the development and maintenance of prostatic inflammatory reactions. METHODS: In a retrospective study the data of 110 patients who presented with lower urinary tract symptoms suggestive of prostatitis, from January 1994 to February 1999 have been evaluated: 65 of this patients had an abacterial prostatitis, and 45 a bacterial prostatitis. The Mearers-Stamey test was used to localize inflammation and pathogens to prostate. The clinical symptoms presented were essentially pelvic and perineal pain and irritative and obstructive voiding symptoms. The treatment was based on antibiotic therapy indicated by the sensitivity to antibiotic assay. In abacterial prostatitis, in cases of Chlamidia, Mycoplasma and Ureaplasma positivity, the treatment was based on macrolides and tetracycline use. All the patients received Mepartricine by oral supply, 1 daily tablet (40 mg) for 60 days. RESULTS: After two months of treatment remarkable improvements in symptoms were obtained despite the persistent bacteriological positivity in the prostatic secretion in 68% of cases. Therefore antinflammatory antiedemic and decongestant effects of Mepartricine on prostatic inflammation, are observed. CONCLUSIONS: The data of the literature show data estrogens modulate inflammatory reactions: it is possible that their decrease can produce, at prostatic level, antinflammatory effects improving urethro-prostatic bladder functions. Personal experience seems to confirm this supposition and so we think that Mepartri-cine can be considered and excellent coadjuvant in the treatment of prostate inflammation, independent of etiology.
[Mh] Termos MeSH primário: Mepartricina/uso terapêutico
Prostatite/tratamento farmacológico
[Mh] Termos MeSH secundário: Adulto
Seres Humanos
Masculino
Meia-Idade
Estudos Retrospectivos
[Pt] Tipo de publicação:ENGLISH ABSTRACT; JOURNAL ARTICLE
[Nm] Nome de substância:
11121-32-7 (Mepartricin)
[Em] Mês de entrada:0208
[Cu] Atualização por classe:170126
[Lr] Data última revisão:
170126
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:011128
[St] Status:MEDLINE


  10 / 91 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:11516265
[Au] Autor:Re G; Badino P; Odore R; Vigo D; Bonabello A; Rabino S; Capello F; Bruzzese T
[Ad] Endereço:Department of Animal Pathology, Division of Pharmacology & Toxicology, University of Torino, via Leonardo da Vinci 44, I-10095 Grugliasco (TO), Italia. re@veter.unito.it
[Ti] Título:Effects of mepartricin on estradiol and testosterone serum levels and on prostatic estrogen, androgen and adrenergic receptor concentrations in adult rats.
[So] Source:Pharmacol Res;44(2):141-7, 2001 Aug.
[Is] ISSN:1043-6618
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:The effects induced by oral administration of 0, 5 and 20 mg of meparticin kg(-1)of body weight for 28 days (group 1, 2 and 3, respectively) upon prostatic estrogen, androgen, alpha(1)- and beta-adrenergic receptor concentrations and on estradiol and testosterone serum levels in adult male rats were studied. The effects produced by mepartricin treatments on the weight and dimension of the gland were investigated. Both mepartricin dosages induced significant decreases (P< 0.05) of the absolute and relative weights and of the dimensions of the prostate. A significant dose-dependent decrease (P< 0.05) in estradiol serum levels was observed in treated rats, whereas no significant modifications were found in testosterone serum levels. As far as prostatic steroid receptor concentrations were concerned, a significant (P< 0.05) decrease in estrogen receptor number was observed in both treated groups, whilst a significant increase (P< 0.05) of androgen receptor concentrations was recorded only in rats treated with 20 mg mepartricin kg(-1). Conversely, a dose-dependent up-regulation of both prostatic alpha(1)- and beta-AR was found. Data obtained suggest that the prostatic alpha(1)-AR expression may be strongly influenced by estrogen deprivation (mepartricin treatment), therefore the combination of estrogen suppression (mepartricin) and adrenergic suppression (alpha(1)-AR blockers) may be suggested as a possible pharmacotherapeutic strategy for the treatment of benign prostatic hyperplasia.
[Mh] Termos MeSH primário: Antibacterianos/farmacologia
Estradiol/sangue
Mepartricina/farmacologia
Próstata/efeitos dos fármacos
Testosterona/sangue
[Mh] Termos MeSH secundário: Administração Oral
Animais
Antibacterianos/efeitos adversos
Masculino
Mepartricina/efeitos adversos
Tamanho do Órgão/efeitos dos fármacos
Próstata/diagnóstico por imagem
Próstata/metabolismo
Próstata/patologia
Hiperplasia Prostática/sangue
Hiperplasia Prostática/induzido quimicamente
Hiperplasia Prostática/diagnóstico por imagem
Ratos
Ratos Sprague-Dawley
Receptores Adrenérgicos/metabolismo
Receptores Androgênicos/metabolismo
Receptores Estrogênicos/metabolismo
Ultrassonografia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Receptors, Adrenergic); 0 (Receptors, Androgen); 0 (Receptors, Estrogen); 11121-32-7 (Mepartricin); 3XMK78S47O (Testosterone); 4TI98Z838E (Estradiol)
[Em] Mês de entrada:0112
[Cu] Atualização por classe:161124
[Lr] Data última revisão:
161124
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:010823
[St] Status:MEDLINE



página 1 de 10 ir para página                        
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde